As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
Activists with Black Lives Matter, who met privately with Buttigieg in the weeks after police shot and killed Eric Logan, say the 37-year-old mayor brushed off their concerns...2020 Electionsread more
Trump said he "is revoking" a federal waiver that allowed the state to craft its own rules on greenhouse gas emissions from vehicles.Politicsread more
Wall Street economists think the Fed will cut rates by 25 basis points at its September meeting but have differing views about what will happen in the future.Marketsread more
FedEx CEO Fred Smith mentioned Amazon as one of his competitors during Tuesday's earnings call, a shift in stance for a company that's long downplayed Amazon's move into the...Technologyread more
J.P. Morgan Chase chief Dimon says he doesn't think the U.S. is close to recession and called the Fed's Powell "a quality human."Marketsread more
Check out the companies making headlines in midday trading.Market Insiderread more
Drone and missile debris recovered by investigators at the Saudi Aramco attack site is proof of Iranian culpability, a Saudi defense ministry representative told media on...World Politicsread more
FedEx CEO Fred Smith is "basically implying that we're going to import" a global slowdown, says CNBC's Jim Cramer.Investingread more
Fans of "The Princess Bride" are screaming "inconceivable!" after the CEO of Sony Pictures Entertainment said pitches had been made by "very famous people" to remake the...Entertainmentread more
The unspecified action comes after the U.S. accused Iran of carrying out the weekend attacks on critical Saudi oil installations.Politicsread more
What the heck is Jim Cramer supposed to make out of the breathtaking Axovant Sciences? It hit the tape as the biggest biotech IPO ever on Thursday, and skyrocketed 99 percent right out of the gate.
Axovant went public at $15 on Thursday, and closed at $29—which makes Cramer a bit worried that things have gotten ahead of themselves with the stock because the target end market is so large. The company currently has one drug in its pipeline, RVT-101, which is an orally administered therapy designed to help patients with Alzheimer's disease.
The company acquired the drug from GlaxoSmithKline for $5 million last December. Results of a phase 2 study revealed that while the drug did help to alleviate symptoms of Alzheimer's, it didn't actually change the course of the disease.
"It is worth mentioning that this clinical trial has been viewed with skepticism by a number of people in the biotech community, although the strength of the IPO says that it doesn't pay to be too skeptical, at least when it comes to getting in on this deal," the "Mad Money" host said.
Axovant plans to move its drug into phase 3 trials later this year, and if everything goes well then Cramer thinks this could be a compelling story. However, he worries that investors have a long history of getting burned by potential Alzheimer's drugs that appear to be attractive, but never actually make it to market.
Given the fact that GlaxoSmithKline sold the drug to Axovant for $5 million upfront, along with a few milestone payments and royalties, could it really be worth the current valuation of Axovant at $2.2 billion?
To make the company even more interesting, Axovant's CEO Vivek Ramaswamy is just 29 years old and was featured in Forbes' 30 Under 30 list last year. As a former partner at QVT Financial, he left the firm and founded Roivant Sciences, sits on the board of OnCore Biopharma and is chairman of the board of Tekmira Pharmaceuticals. He also achieved a degree in biology from Harvard College, and J.D. degree from Yale Law School—while working at QVT Financial.
Is Axovant's drug the real deal? To find out more about the company's trajectory, Cramer spoke with Ramaswamy.
The CEO stated that he has confidence in Axovant's drug, as it could help the 5 million patients in the U.S. with Alzheimer's disease. The company's focus is not only on the treatment of Alzheimer's, but also dementia and other forms of dementia.
His confidence stems from the strength of his team, including the developer of the most widely used drug to treat Alzheimer's disease, along with board members that include the former head of neuroscience from GlaxoSmithKline who led the development of this drug.
Read more from Mad Money with Jim Cramer
Cramer Remix: Greece talks could fail
Cramer: Do you have $$ loss mentality?
Cramer: Good signs hidden in the market
"The thing in Alzheimer's disease to remember, and we remember this all the time at Axovant, is we don't fully understand the way the actual underlying disease works. Not just us at Axovant, but the field more generally," Ramaswamy said.
The CEO added that RVT-101 is a neurotransmitter targeted therapy that works through the release of acetylcholine, which is already known to be an effective treatment. Thus, the drug utilizes already effective methods of treatment and, according to Ramaswamy, is a well-tolerated drug that can be taken in pill form once a day.
"We believe we are only one additional phase 3 study away from the approval of this drug on a global basis," Ramaswamy added.